CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catamaran Bio, Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, today announced new data demonstrating preclinical efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback